Studies of colchicine in people
6 studies gave colchicine to people and measured what changed
| What changed | Design | People | Source |
|---|---|---|---|
no change: Has no effect on aortic FDG uptakeAdjusted mean change 0.05 versus 0.01 with placebo; p=0.38 down: Decreases neutrophil-to-lymphocyte ratioAdjusted mean change −0.36 versus −0.08; p=0.033 down: Decreases blood pressureSystolic change 0.88 versus 4.94 mmHg (p=0.046); diastolic change 1.41 versus 4.35 mmHg (p=0.048) | Randomized trial24 weeks | 111 peopleChronic coronary artery disease | Cardiovascular research, Nov 7, 2026 |
no change: Has no effect on cardio-ankle vascular indexBetween-group difference 0.17, 95% CI -0.18 to 0.51; p=0.35 no change: Has no effect on C-reactive proteinMean changes 0.42 versus 0.25 mg/L; p=0.78 | Randomized trial6 months | 60 peopleBoth40 to 60 years; mean 53.2 yearsMidlife adults; type 2 diabetes without established atherosclerotic cardiovascular disease | ESC Congress 2026 abstract, Oct 26, 2026 |
no change: Has no effect on left ventricular systolic and diastolic function down: Decreases tricuspid annular plane systolic excursion-0.26 cm (95% CI -0.40 to -0.11); values remained within the normal clinical range down: Decreases leukocyte countBetween-group difference in percent change: -8.0% (95% CI -13.5 to -2.5); p=0.004 | Randomized trial6 months | 150 peopleadultsWell-controlled hypertension without other known cardiovascular disease | ESC Congress 2026 abstract, Oct 26, 2026 |
down: Decreases leukocyte countP=0.02 no change: Has no effect on C-reactive protein | Randomized trial4 weeks | 48 peopleBothmean age 70±6 yearsOlder adults; Patient cohorts | ESC Congress 2026 abstract, Oct 26, 2026 |
no change: Has no effect on carotid-femoral pulse wave velocityBetween-group difference in change -0.1 m/s (95% CI -0.5 to 0.3); p=0.53 up: Increases office systolic blood pressureBetween-group difference in change +5.7 mmHg (95% CI 1.0 to 10.5); p=0.018 down: Decreases C-reactive proteinBetween-group difference in percent change -39.8% (95% CI -59.1 to -11.4); p=0.010 | Randomized trialsix months | 150 peopleBoth64.5 (±8.0) yearsOlder adults; pharmacologically treated hypertension without cardiovascular disease | European journal of preventive cardiology, Oct 16, 2026 |
no change: Has no effect on cardiovascular mortalityHR 0.80; 95% CI 0.44–1.44 | Randomized trialmedian 28.6 months | 5,522 peopleChronic coronary disease | International journal of cardiology, Dec 15, 2022 |